Home Capital Broker's Calls

'Buy' Raffles Medical, as it benefits from Singapore's reopening: analysts

Amala Balakrishner
Amala Balakrishner7/13/2021 1:53 AM GMT+08  • 3 min read
'Buy' Raffles Medical, as it benefits from Singapore's reopening: analysts
Jaiswal is maintaining his “buy” call on the company at a revised target price of $1.35.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Raffles Medical is set to benefit from Singapore’s re-opening, says RHB Securities analyst Shekhar Jaiswal.

“The accelerated vaccination programme and continued testing as the country relaxes restrictions and looks to reopen borders by the year end should continue to support near-term revenue and earnings,” he adds.

Jaiswal’s comments come as Raffles Medical provides Covid-19 testing at its 36 clinics. It was also one of the six firms to be awarded contracts to provide testing services at regional screening centres and dormitories.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.